(Q34504202)

2 August 2017

1 reference

title

The treatment challenge of hormone-refractory prostate cancer (English)

1 reference

2 August 2017

1 reference

Satish T S Bukkapatnam

1 reference

ORCID Public Data File 2021

author name string

Kish JA

series ordinal

1

1 reference

2 August 2017

Bukkapatnam R

series ordinal

2

1 reference

2 August 2017

Palazzo F

series ordinal

3

1 reference

2 August 2017

publication date

1 November 2001

1 reference

2 August 2017

1 reference

2 August 2017

volume

8

1 reference

2 August 2017

issue

6

1 reference

2 August 2017

page(s)

487-495

1 reference

Prostate Cancer: Screening, Diagnosis, and Management

2 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F107327480100800603

A controlled trial of leuprolide with and without flutamide in prostatic carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480100800603

Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480100800603

Hormone-refractory (D3) prostate cancer: refining the concept.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480100800603

A reevaluation of nonhormonal cytotoxic chemotherapy in the treatment of prostatic carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480100800603

Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480100800603

Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480100800603

Chemotherapy for patients with advanced prostate carcinoma: a new option for therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480100800603

Mechanism of androgen receptor activation and possible implications for chemoprevention trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480100800603

Clinical trials in relapsed prostate cancer: defining the target

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480100800603

Flutamide withdrawal syndrome: its impact on clinical trials in hormone-refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480100800603

The antiandrogen withdrawal syndrome. Experience in a large cohort of unselected patients with advanced prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480100800603

Current clinical trial design issues in hormone-refractory prostate carcinoma. Consensus Panel

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480100800603

Low doses of oral dexamethasone for hormone-refractory prostate carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480100800603

Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480100800603

Mechanisms of action and clinical uses of estramustine

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480100800603

Phase II study of estramustine and vinblastine, two microtubule inhibitors, in hormone-refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480100800603

Phase I trial of the combination of daily estramustine phosphate and intermittent docetaxel in patients with metastatic hormone refractory prostate carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480100800603

Doxorubicin and dose-escalated cyclophosphamide with granulocyte colony-stimulating factor for the treatment of hormone-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480100800603

A phase II study of temozolomide in hormone-refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480100800603

Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480100800603

The assessment of treatment outcomes in metastatic prostate cancer: changing endpoints

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480100800603

Prognostic significance of extent of disease in bone in patients with androgen-independent prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480100800603

Prognostic indicators in hormone refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480100800603

Observations on the early detection of prostate cancer from the American Cancer Society National Prostate Cancer Detection Project

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480100800603

Phase II evaluation of oral estramustine and oral etoposide in hormone-refractory adenocarcinoma of the prostate

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480100800603

Oral estramustine and oral etoposide for hormone-refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480100800603

10.1177/107327480100800603

21 January 2018

Identifiers

DOI

0 references

1 reference